1. Search Result
Search Result
Results for "

Covid-19

" in MedChemExpress (MCE) Product Catalog:

399

Inhibitors & Agonists

1

Screening Libraries

3

Fluorescent Dyes

7

Biochemical Assay Reagents

14

Peptides

28

Inhibitory Antibodies

49

Natural
Products

12

Recombinant Proteins

35

Isotope-Labeled Compounds

11

Oligonucleotides

1

GMP Molecules

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-17589A
    Chloroquine
    Maximum Cited Publications
    1191 Publications Verification

    Parasite Autophagy SARS-CoV Toll-like Receptor (TLR) HIV Antibiotic Infection Inflammation/Immunology Cancer
    Chloroquine is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC50=1.13 μM) .
    Chloroquine
  • HY-17589
    Chloroquine phosphate
    Maximum Cited Publications
    1191 Publications Verification

    Parasite Autophagy SARS-CoV Toll-like Receptor (TLR) HIV Antibiotic Infection Inflammation/Immunology Cancer
    Chloroquine phosphate is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine phosphate is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine phosphate is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC50=1.13 μM) .
    Chloroquine phosphate
  • HY-15407
    Sacubitril
    3 Publications Verification

    AHU-377

    Neprilysin Infection Cardiovascular Disease
    Sacubitril (AHU-377) is a potent and orally active NEP (neprilysin) inhibitor with an IC50 of 5 nM. Sacubitril is a component of the heart failure medicine LCZ696. Sacubitril can be used for the research of heart failure, hypertension and COVID-19 .
    Sacubitril
  • HY-135853
    Molnupiravir
    70+ Cited Publications

    EIDD-2801; MK-4482

    SARS-CoV Influenza Virus Infection
    Molnupiravir (EIDD-2801) is an orally bioavailable proagent of the ribonucleoside analog EIDD-1931. Molnupiravir has broad spectrum antiviral activity against influenza virus and multiple coronaviruses, such as SARS-CoV-2, MERS-CoV, SARS-CoV. Molnupiravir has the potential for the research of COVID-19, and seasonal and pandemic influenza .
    Molnupiravir
  • HY-16050
    Plitidepsin
    4 Publications Verification

    Aplidine; PM90001

    DNA/RNA Synthesis SARS-CoV Infection Cancer
    Plitidepsin (Aplidine) is a potent anti-cancer agent by targeting eEF1A2 ( KD=80 nM) . Plitidepsin possesses antiviral activity and is against SARS-CoV-2 with an IC90 of 0.88 nM. Plitidepsin is usually used for multiple myeloma and advanced cancer research, and has the potential for COVID-19 research .
    Plitidepsin
  • HY-P9956
    Siltuximab
    3 Publications Verification

    CNTO-328

    Interleukin Related Cancer
    Siltuximab is an anti-IL-6 (interleukin-6) monoclonal antibody, and shows antitumor activity. Siltuximab can be used in Multicentric Castleman's Disease (MCD) and COVID-19 research .
    Siltuximab
  • HY-146246
    EIDD-2749
    5 Publications Verification

    4'-FlU; 4'-Fluorouridine

    RSV SARS-CoV HCV Infection
    EIDD-2749 (4'-Fluorouridine) is an orally active RdRp inhibitor. EIDD-2749 effectively blocks the replication of RSV and SARS-CoV-2. EIDD-2749 also exhibits activity against HCV and lymphocytic choriomeningitis virus (LCMV). EIDD-2749 is a promising oral therapeutic candidate for COVID-19 and is also suitable for research on other RNA viruses .
    EIDD-2749
  • HY-P99207
    Lenzilumab
    1 Publications Verification

    KB 003

    SARS-CoV Cancer
    Lenzilumab (KB 003) is a human monoclonal antibody targeting CSF2/GM-CSF for COVID-19, chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) studies .
    Lenzilumab
  • HY-153083

    mRNA SARS-CoV Infection
    COVID-19 Spike Protein mRNA (N1-Me-Pseudo UTP) is an mRNA encoding the SARS-CoV-2 spike protein with enhanced performance via chemical modification. COVID-19 Spike Protein mRNA (N1-Me-Pseudo UTP) replaces natural uridine (UTP) with N1-Me-Pseudo UTP, which effectively reduces immunogenicity and improves stability and translation efficiency. The 3' UTR of COVID-19 Spike Protein mRNA (N1-Me-Pseudo UTP) optimizes AU-rich elements through HuR anchor sites, exhibiting higher translation efficiency. COVID-19 Spike Protein mRNA is widely used in COVID-19-related scientific research and vaccine development .
    COVID-19 Spike Protein mRNA(N1-Me-Pseudo UTP)
  • HY-15407B
    Sacubitril sodium
    3 Publications Verification

    AHU-377 sodium

    Neprilysin Infection Cardiovascular Disease
    Sacubitril sodium is a potent and orally active NEP (neprilysin) inhibitor, with an IC50 of 5 nM. Sacubitril sodium enhances the tone of the natriuretic peptide (NP) system and exerts significant antihypertensive effects. Sacubitril sodium is a component of the heart failure medicine LCZ696. Sacubitril sodium can be used for the research of heart failure, hypertension and COVID-19 .
    Sacubitril sodium
  • HY-17015A
    Peramivir
    10+ Cited Publications

    RWJ-270201; BCX-1812

    IKK JNK STAT p38 MAPK ERK Infection Inflammation/Immunology
    Peramivir is an novel cyclopentane neuraminidase inhibitor of influenza virus. Peramivir has antiviral activity and anti-cytokines stom effects. Peramivir can be used for the research of COVID-19 .
    Peramivir
  • HY-17589B
    Chloroquine dihydrochloride
    Maximum Cited Publications
    1191 Publications Verification

    Parasite Autophagy SARS-CoV Toll-like Receptor (TLR) HIV Antibiotic Infection Inflammation/Immunology Cancer
    Chloroquine dihydrochloride is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine dihydrochloride is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine dihydrochloride is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC50=1.13 μM) .
    Chloroquine dihydrochloride
  • HY-13591
    Piclidenoson
    5+ Cited Publications

    IB-MECA; CF-101

    Adenosine Receptor Apoptosis Inflammation/Immunology Cancer
    Piclidenoson (IB-MECA) is a first-in-class, orally active and selective A3 adenosine receptor (A3AR) agonist. Piclidenoson exhibits antiproliferative effect and induces apoptosis in different cancer cell types like melanoma, leukemia. Piclidenoson can be used for the research of autoimmune inflammatory diseases and COVID-19 .
    Piclidenoson
  • HY-145119AS

    VV116; GS-621763-d1 hydrobromide

    SARS-CoV RSV Influenza Virus Infection
    Mindeudesivir (JT001; VV116; GS-621763-d1) hydrobromide is a deuterated version of Remdesivir (HY-104077), a highly orally active nucleoside antiviral against SARS-CoV-2 and respiratory syncytial virus (RSV). Mindeudesivir hydrobromide retains the antiviral activity of Remdesivir against COVID-19, and is the first domestically produced deuterium targeting the COVID-19 .
    Mindeudesivir hydrobromide
  • HY-153235

    mRNA SARS-CoV Liposome Infection
    COVID-19 Spike Protein mRNA-LNP is a lipid nanoparticle (LNP) containing mRNA encoding COVID-19 Spike Protein. COVID-19 Spike Protein undertakes the functions of virus binding with host cell receptors, thereby mediating the entry of COVID-19 virus into cells. COVID-19 Spike Protein is an important site of action for host neutralizing antibodies and a key target for vaccine design. COVID-19 Spike Protein mRNA-LNP can be used for RNA delivery, vaccine formulation and design targeting SARS-CoV-2 .
    COVID-19 Spike Protein mRNA-LNP
  • HY-P2295
    Dabcyl-KTSAVLQSGFRKME-Edans TFA
    2 Publications Verification

    SARS-CoV Others
    Dabcyl-KTSAVLQSGFRKME-Edans TFA is a fluorogenic peptide. Dabcyl-KTSAVLQSGFRKME-Edans TFA is used as the substrate to measure the enzymatic activities of protease forms. Dabcyl-KTSAVLQSGFRKME-Edans TFA has the potential for study 2019-nCoV (COVID-19) infection .
    Dabcyl-KTSAVLQSGFRKME-Edans TFA
  • HY-P99520

    CaCP-29, IFX-1

    Complement System SARS-CoV Infection Inflammation/Immunology
    Vilobelimab (CaCP-29, IFX-1) is a monoclonal anti-C5a antibody to the allergen C5a, a pro-inflammatory complement division product that plays a central role in mediating organ dysfunction. Vilobelimab acts as a C5a inhibitor, inhibiting neutrophil activation, chemotaxis, and reducing inflammatory signalling, and may be used in studies related to sepsis, COVID-19, etc .
    Vilobelimab
  • HY-107577

    HSP Infection Inflammation/Immunology Cancer
    Gedunin is a limonoid with anti-cancer, anti-viral, anti-inflammatory and insecticidal activities. Gedunin acts as a potent Hsp90 inhibitor and induces the degradation of Hsp90-dependent client proteins. Geduni may obstructs the entry of SARS-CoV-2 virus into human host cells and can be used for COVID-19 research .
    Gedunin
  • HY-17589AR
    Chloroquine (Standard)
    1 Publications Verification

    Reference Standards Parasite Autophagy SARS-CoV Toll-like Receptor (TLR) HIV Antibiotic Infection Inflammation/Immunology Cancer
    Chloroquine (Standard) is the analytical standard of Chloroquine. This product is intended for research and analytical applications. Chloroquine is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC50=1.13 μM) .
    Chloroquine (Standard)
  • HY-N6787
    5,6-Dihydro-5-methyluracil
    3 Publications Verification

    Dihydrothymine

    Endogenous Metabolite Infection
    5,6-Dihydro-5-methyluracil (Dihydrothymine) is an intermediate breakdown product of Thymine (HY-W010450). 5,6-Dihydro-5-methyluracil can be used as a marker of DNA damage. 5,6-Dihydro-5-methyluracil can be used for the research of COVID-19 .
    5,6-Dihydro-5-methyluracil
  • HY-P99779

    TJ003234; TJM2

    c-Fms SARS-CoV Infection Inflammation/Immunology
    Plonmarlimab (TJ003234) is an anti-GM-CSF monoclonal antibody. Plonmarlimab can be used for research of rheumatoid arthritis and COVID-19 .
    Plonmarlimab
  • HY-P99919
    Efmarodocokin alfa
    1 Publications Verification

    Interleukin Related Infection
    Efmarodocokin alfa is a fusion protein of human IL-22 and the IgG4 crystallizable fragment. Efmarodocokin alfa activates IL-22 signaling. Efmarodocokin alfa can be used for the research of severe COVID-19 pneumonia .
    Efmarodocokin alfa
  • HY-P990766

    AZD3152

    SARS-CoV Infection
    Sipavibart (AZD3152) is a human IgG1 λ2 monoclonal antibody against SARS-CoV-2. Sipavibart is applicable to research related to COVID-19. The isotype control product for Sipavibart is Human IgG1 lambda2, Isotype Control (HY-P990096) .
    Sipavibart
  • HY-136303
    GS-704277
    3 Publications Verification

    Drug Metabolite Infection
    GS-704277 is an alanine metabolite of Remdesivir (HY-104077). GS-704277 is further hydrolyzed to GA-441524 (HY-103586) with antiviral activity. Remdesivir, a nucleoside analogue with effective antiviral activity, is highly effective in the control of SARS-CoV-2 (COVID-19) infection .
    GS-704277
  • HY-132850

    BLD-2660

    Proteasome Interleukin Related Infection Inflammation/Immunology
    Dazcapistat (BLD-2660) is an orally active small-molecule inhibitor of calpain 1, 2, and 9 (calpain 1, 2, 9). Dazcapistat reduces the expression/production level of IL-6 in injured lung tissue and alleviates fibrosis . Dazcapistat exerts anti-fibrotic effects in various animal models of fibrosis in the skin, liver and lung . Dazcapistat can be used in research related to coronavirus disease 2019 (COVID-19) and idiopathic pulmonary fibrosis .
    Dazcapistat
  • HY-P99642

    MORAb-022

    c-Fms SARS-CoV Infection Inflammation/Immunology
    Gimsilumab (MORAb-022) is a human anti-GM-CSF monoclonal antibody. Gimsilumab has the potential for the research of COVID-19 and rheumatoid arthritis (RA) .
    Gimsilumab
  • HY-145656

    3-Oxo-7α-hydroxy-5β-cholanoic acid

    Endogenous Metabolite Metabolic Disease
    3-Oxochenodeoxycholic acid is an endogenous metabolite that can be found in feces. 3-Oxochenodeoxycholic acid can serve as an indicator for the diagnosis of certain diseases, such as COVID-19 .
    3-Oxochenodeoxycholic acid
  • HY-P99103

    LY-3853113; LY-COV1404

    SARS-CoV Infection
    Bebtelovimab a human IgG1-λ2 antibody targeting to SARS-CoV-2, especially COVID-19 ((the IC50 value for SARS-CoV-2/MT020880.1 virus is 9-22.1 ng/mL)). Bebtelovimab potently neutralizes SARS-CoV-2 variants, and inhibits COVID-19 with mild-to-moderate efficacy .
    Bebtelovimab
  • HY-N16395

    SARS-CoV Virus Protease Infection
    Jensenone is an acylphloroglucinol derivative. Jensenone binds to COVID-19 proteinase in molecular docking studies. Jensenone can be used as a COVID-19 Mpro inhibitor .
    Jensenone
  • HY-P99490

    hzVSF-v13

    Interleukin Related SARS-CoV Infection Inflammation/Immunology
    Burfiralimab (hzVSF-v13) is a monoclonal IgG4 antibody against vimentin expressed on the surface of virus-infected cells, with broad-spectrum antiviral activity and anti-inflammatory effects against virus-induced inflammation. Burfiralimab can be used in severe COVID-19 studies .
    Burfiralimab
  • HY-135909
    TH1217
    1 Publications Verification

    ZINC1775962367

    SARS-CoV Infection Cancer
    TH1217 (ZINC1775962367) is a potent and selective dCTPase pyrophosphatase 1 (dCTPase) inhibitor, with an IC50 of 47 nM. TH1217 enhances the cytotoxic effect of cytidine analogues in leukemia cells. TH1217 also could modulate SARS-Cov-2 interactors, so it shows activity of against COVID-19 .
    TH1217
  • HY-145592

    RO7020531; RG7854

    Toll-like Receptor (TLR) SARS-CoV HBV Infection
    Ruzotolimod (RO7020531) is an orally active TLR7 agonist. Ruzotolimod inhibits WHV viral replication and, in combination with RO-7049389 (HY-145579), inhibits AAV-HBV viral load. Ruzotolimod can be used to study infection with COVID-19 or SARS-CoV-2 .
    Ruzotolimod
  • HY-147020

    NK01-63

    SARS-CoV Infection
    Coronastat is a potent inhibitor of the SARS-CoV-2 3CL protease. The SARS-CoV-2 3CL protease is a critical agent target for small molecule COVID-19, given its likely agentgability and essentiality in the viral maturation and replication cycle .
    Coronastat
  • HY-P99012

    Interleukin Related SARS-CoV Infection Inflammation/Immunology
    Clazakizumab is a monoclonal antibody with high affinity and specificity for the IL-6 (interleukin-6) cytokine. Clazakizumab may be helpful in inhibiting the cytokine response to SARS-CoV-2 in COVID-19. Clazakizumab can be used for the research of psoriatic arthritis (PsA) and renal antibody-mediated rejection .
    Clazakizumab
  • HY-151482

    SARS-CoV Infection
    SARS-CoV-2 Mpro-IN-2 (compound GC-14) is a selective, low cytotoxic and non-covalent M pro inhibitor (IC50=0.40 μM) with good anti-SARS-CoV-2 activity (EC50=1.1 μM). SARS-CoV-2 Mpro-IN-2 can be used in COVID-19 studies .
    SARS-CoV-2 Mpro-IN-2
  • HY-134783

    Liposome Others
    1,19-Bis(2-butyloctyl) 10-[[3-(dimethylamino)propyl](1-oxononyl)amino]nonadecanedioate is an excipient for vaccines. 1,19-Bis(2-butyloctyl) 10-[[3-(dimethylamino)propyl](1-oxononyl)amino]nonadecanedioate can be used for the research of the development of COVID-19 vaccines and drug delivery for gene therapy .
    1,19-Bis(2-butyloctyl) 10-[[3-(dimethylamino)propyl](1-oxononyl)amino]nonadecanedioate
  • HY-P99341
    Casirivimab
    1 Publications Verification

    REGN10933

    SARS-CoV Infection
    Casirivimab (REGN10933) is a human monoclonal antibody that targets the SARS-CoV-2 virus, which causes COVID-19. Casirivimab is ineffective against COVID-19 variants. Casirivimab can be used in combination with Imdevimab (HY-P99342), which alters the lung response of K18-hACE2 mice to the SARS-CoV-2 δ variant, effectively reducing viral load and improving symptoms .
    Casirivimab
  • HY-P99226

    MEDI7734; VIB7734

    SARS-CoV Human leukocyte immunoglobulin (Ig)-like receptors (LILR) Cancer
    Daxdilimab is an anti-ILT7 monoclonal antibody, ILT7 is a cell surface molecule specific to the pDC type of dendritic cells. Daxdilimab can be used in acute lung injury (ALI) in patients with COVID-19 infection research .
    Daxdilimab
  • HY-P99346

    CT-P59

    SARS-CoV Angiotensin-converting Enzyme (ACE) Infection
    Regdanvimab (CT-P59) is a human monoclonal antibody that targets the receptor-binding domain of SARS-CoV-2 spike protein, blocking interaction with ACE2 for viral entry. Regdanvimab can be used for the research of COVID-19 .
    Regdanvimab
  • HY-17589AS
    Chloroquine-d5
    1 Publications Verification

    Isotope-Labeled Compounds Parasite Autophagy SARS-CoV Toll-like Receptor (TLR) HIV Infection Inflammation/Immunology Cancer
    Chloroquine-d5 is deuterium labeled Chloroquine (HY-17589A). Chloroquine is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC50=1.13 μM) .
    Chloroquine-d5
  • HY-108044

    Cathepsin SARS-CoV Metabolic Disease
    ONO-5334 is a potent, selective and orally active cathepsin K inhibitor with Ki values of 0.10 nM, 0.049 nM and 0.85 nM for human, rabbit and rat cathepsin K, respectively. ONO 5334 is an effective antiviral compound against SAR-COV-2 virus activity with an EC50 value of 500 nM. ONO-5334 has the potential for the study of osteoporosis and COVID-19 disease .
    ONO-5334
  • HY-149373

    Angiotensin-converting Enzyme (ACE) SARS-CoV Infection
    Garcinone B, a xanthone derivative, is a nature product that could be isolated from the pericarp of Mangosteen. Garcinone B is a potent ACE2 and Mpro inhibitor. Garcinone B can be used in research of COVID-19 .
    Garcinone B
  • HY-132849

    TD-0903

    JAK Infection Inflammation/Immunology
    Nezulcitinib (TD-0903) is an inhaled and lung-selective pan-Janus kinase (JAK) inhibitor. Nezulcitinib can be used for the research of COVID-19 associated acute lung injury and impaired oxygenation .
    Nezulcitinib
  • HY-151477

    SARS-CoV Infection Cancer
    SARS-CoV-2-IN-32 (compound 3g) is a COVID-19 inhibitor. SARS-CoV-2-IN-32 shows anti-proliferative activity against cancer cells. SARS-CoV-2-IN-32 exhibits comparatively high binding affinity (-8.8 Kcal/mole) to COVID-19 main protease (M pro) (PDB ID: 6LU7). SARS-CoV-2-IN-32 can be used in studies of cancer and COVID-19 .
    SARS-CoV-2-IN-32
  • HY-132306
    CCF0058981
    1 Publications Verification

    CCF981

    SARS-CoV Virus Protease Infection
    CCF0058981 (CCF981), 3-chlorophenyl analogue, is a noncovalent SARS-CoV-2 3CL pro (SC2) inhibitor with an IC50 of 68 nM. CCF0058981 inhibits SC1 (SARS-CoV-1 3CL pro) with an IC50 of 19 nM. CCF0058981 has antiviral efficacy and has the potential for COVID-19 research .
    CCF0058981
  • HY-100546

    Histone Demethylase Infection Metabolic Disease Cancer
    GSK-LSD1, a chemical probe, is a LSD1 inhibitor. GSK-LSD1 reduces food intake and body weight, and improves insulin sensitivity and glycemic control in mouse models of obesity. GSK-LSD1 also ameliorates NAFLD. GSK-LSD1 inhibits SARS-CoV-2-triggered cytokine release in COVID-19 PBMCs. GSK-LSD1 also inhibits cancer growth and metastasis .
    GSK-LSD1
  • HY-150622

    SARS-CoV Infection
    SARS-CoV-2 nsp13-IN-1 (compound C1) is a potent nsp13 (non-structural protein 13) inhibitor. SARS-CoV-2 nsp13-IN-1 only inhibits nsp13 ssDNA + ATPase, with an IC50 of 6 μM. SARS-CoV-2 nsp13-IN-1 does not inhibit ssDNA - ATPase. SARS-CoV-2 nsp13-IN-1 can be used for COVID-19 research .
    SARS-CoV-2 nsp13-IN-1
  • HY-105721

    SARS-CoV Infection
    Aranotin strongly binds to Nsp15 viral protein. Aranotin can be used as promising SARS-CoV-2 replication strong inhibitor. Aranotin has the potential for COVID-19 research .
    Aranotin
  • HY-172223

    C3Guo

    SARS-CoV Infection
    3-Deazaguanosine (C3Guo) has potent antiviral activity against SARS-CoV-2 (EC50: 1.14 μM, CC50: >200 μM for Vero E6 cells). 3-Deazaguanosine prevents COVID-19 pneumonia .
    3-Deazaguanosine
  • HY-176229

    SARS-CoV Cathepsin Virus Protease Infection
    Mpro/Cathepsin L-IN-2 (Compound 1) is a dual irreversible inhibitor of SARS-CoV-2 main protease (M pro, pIC50=8.61) and human cathepsin L (hCTSL, pIC50=7.64). Mpro/Cathepsin L-IN-2 is promising for research of COVID-19 and other coronavirus infections .
    Mpro/Cathepsin L-IN-2

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: